[The significance of determining antibodies to viruses of the Herpesviridae family in rheumatic diseases].

Aim: Assay of antibodies to cytomegalovirus (CMV), herpes simplex virus type 1 and 2 (HSV-1 and HSV-2) and Epstein-Barr virus (EBV) in rheumatic patients. Specification of their correlations with clinical symptoms.

Materials And Methods: 66 rheumatic patients were examined for the above antibodies.

[Significance of antibodies to herpesviridae viruses detectable in rheumatic diseases].

Aim: To assay antibodies to cytomegalovirus (CMV), herpes simplex virus type 1 and 2 (HSV-1, HSV-2) and Epstein-Barr virus (EBV) in rheumatic patients and to clarify clinical correlations.

Materials And Methods: A total of 66 patients were examined: 7, 19, 6, 3, 5, 2 and 24 with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), reactive arthritis (ReA), scleroderma systematica (SS), erythema nodosum (EN), hemorrhagic vasculitis (HV), active or chronic viral infection (A/CVI), respectively. Clinical, laboratory tests, tests for specific IgM- and IgG-antibodies to CMV, HSV-1, HSV-2, EBV, x-ray examinations were performed.

[The isolation and characteristics of long-term continuous lymphoid cell lines (IK-10 and IK-12) from patients with mycosis fungoides].

Examinations of 26 cell cultures have detected in two cases continuous IK-10 and IK-12 cell lines from patients with mycosis fungoides. Studies of these cell ultrastructure, carried out by transmission electron microscopy, have shown organoids of all types, that are characteristic of both minor and medium lymphocytes and of lymphoblasts. Markers of T-, B-cells and mononuclears are also detectable in these cell lines.

[Ultrastructure of the blood lymphoid cells and the dynamics of cellular immunity indices in chronic lympholeukemia patients during immunocorrection with T-activin].

Fourteen patients with chronic lymphoid leukemia who received treatment with T-activin given in courses (800-1100 micrograms) were examined for ultrastructure of blood lymphoid cells and the time-course of changes in humoral immunity. The patients had not received chemotherapy or hormonal treatment before. During the treatment with T-activin, no chemotherapeutic remedies were administered.